- Home
- MGLD vs BNR Comparison
MGLD vs BNR Comparison
Compare MGLD & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- BNR
- Stock Information
- Founded
- MGLD 1996
- BNR 2014
- Country
- MGLD United States
- BNR China
- Employees
- MGLD N/A
- BNR N/A
- Industry
- MGLD Finance/Investors Services
- BNR Medical Specialities
- Sector
- MGLD Finance
- BNR Health Care
- Exchange
- MGLD Nasdaq
- BNR Nasdaq
- Market Cap
- MGLD 80.3M
- BNR 72.4M
- IPO Year
- MGLD N/A
- BNR 2020
- Fundamental
- Price
- MGLD $1.71
- BNR $6.53
- Analyst Decision
- MGLD
- BNR
- Analyst Count
- MGLD 0
- BNR 0
- Target Price
- MGLD N/A
- BNR N/A
- AVG Volume (30 Days)
- MGLD 24.6K
- BNR 28.7K
- Earning Date
- MGLD 02-12-2025
- BNR 12-03-2024
- Dividend Yield
- MGLD N/A
- BNR N/A
- EPS Growth
- MGLD N/A
- BNR N/A
- EPS
- MGLD N/A
- BNR N/A
- Revenue
- MGLD $32,511,000.00
- BNR $72,832,704.00
- Revenue This Year
- MGLD N/A
- BNR $52.90
- Revenue Next Year
- MGLD N/A
- BNR $48.35
- P/E Ratio
- MGLD N/A
- BNR N/A
- Revenue Growth
- MGLD N/A
- BNR N/A
- 52 Week Low
- MGLD $0.78
- BNR $2.62
- 52 Week High
- MGLD $2.10
- BNR $9.80
- Technical
- Relative Strength Index (RSI)
- MGLD 51.19
- BNR 49.85
- Support Level
- MGLD $1.64
- BNR $6.50
- Resistance Level
- MGLD $1.99
- BNR $7.39
- Average True Range (ATR)
- MGLD 0.20
- BNR 0.35
- MACD
- MGLD -0.02
- BNR -0.14
- Stochastic Oscillator
- MGLD 23.68
- BNR 25.41
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.